Featured Research

from universities, journals, and other organizations

Medicare kidney spending reaches crucial moment

Date:
September 4, 2012
Source:
Brown University
Summary:
Medicare has covered treatment for anyone with end-stage renal disease since 1972. The coverage is very expensive and the program has struggled since for 40 years to contain costs without compromising quality. In a new paper that chronicles that history, the authors argue that Medicare's latest attempt -- bundled payments and pay-for-performance -- could become a broader model for the program if it succeeds.

Medicare’s struggle to contain costs: Dialysis and drugs to control anemia became one of Medicare’s biggest costs after 1972, when the program expanded to care for anyone in the country who needed treatment, regardless of age.
Credit: Mike Cohea/Brown University

Amid a presidential campaign and facing the "fiscal cliff," Americans hear a lot about federal spending, particularly for Medicare. But few probably know of either the history or the present watershed moment in the program's 40-year struggle to contain costs and finance quality treatment for Americans with end-stage renal disease. In a timely new paper in the September edition of the journal Health Affairs, researchers chronicle the history of how Medicare has provided one of its most costly services, and point out that a new strategy, if successful, could become a fiscal model for the entire program.

Related Articles


In end-stage renal disease, kidney failure leaves dialysis as the only means of survival. It became one of Medicare's biggest costs after 1972, when the program expanded to care for anyone in the country who needed treatment, regardless of age. Dialysis is expensive and the costs to purchase related anemia drugs is Medicare's single biggest drug expenditure, amounting to $3.9 billion in 2007.

Last year, after decades of trying to balance cost and quality through traditional financing adjustments, Medicare made considerably more dramatic reforms, write the authors from Brown University and the University of Washington. Now policymakers, health care providers and consumers will see whether Medicare's simultaneous moves to bundle total costs and discourage lapses in quality will work.

"One of the key and unique aspects of the dialysis reform is the introduction of bundled payments along with pay-for-performance," said lead author Shailender Swaminathan, assistant professor of health services policy and practice. "The twin payment changes offer a very compelling model of policy reform to rein in health care costs."

But at the same time, Swaminathan notes, history teaches that Medicare has encountered costs it could not predict or prevent, and there is no consensus about what level of hemoglobin (a metric of anemia and therefore of treatment performance) is right for ESRD patients. Without clear quality goals, bundled payments could drive providers to undertreat patients and that could create more costs elsewhere in the system.

40 years of policy changes

When Medicare began ESRD coverage, the authors wrote, it did so on a fee-for-service basis. Costs surged with enrollment, for instance growing to 64,000 patients at a cost of $1.8 billion -- 4 percent of all Medicare spending -- in 1982 compared to 16,000 patients at a cost of $229 million in 1973. The number of patients has continued to rise because diabetes and hypertension rates have increased, Swaminathan said, and because improving medical care allows more patients to reach ESRD.

After the first decade, Medicare tried to cap payments for dialysis. Hospital providers received $131 per treatment and clinic providers received $127. For years, providers saw reimbursements drop in inflation-adjusted terms. With payments based on the number of treatment sessions, not their length, the authors wrote, "there was virtually no financial incentive to provide more dialysis."

In the early 1990s as anemia drugs called erythropoietin stimulating agents (ESAs) came to market, Medicare initially paid on a capitated basis. Economically minded providers responded by giving patients lower doses than recommended: 2,400 units rather than 4,000 units.

Medicare quickly moved to a fee-for-service payment for the ESAs, leading to possible overprescription and the huge rise in costs that made ESAs the program's most expensive drug. Providers treating the disease, after all, were limited in how much they could make providing dialysis, but unlimited in what they could reap providing ESAs.

"Fee-for-service reimbursement for the use of the agents, coupled with the decline in real value of the composite rate for dialysis, motivated providers to increase their use of the agents," the authors wrote.

The new regime

Beginning last year, Medicare implemented a new idea to control costs by implementing total bundled payment for providers for dialysis, drugs, and testing. Now providers receive an average of $230 per session for all three.

"In this new payment regime, providers could no longer maximize their Medicare reiumbursements by increasing the use of [ESAs] or other dialysis-related services," the authors wrote.

Meanwhile they also began imposing penalties on providers whose patients had hemoglobin and urea levels that did not meet standards. But the maximum payment reduction is only 2 percent.

"The pay-for-performance program, which was implemented as a complement to payment bundling, might not independently make a serious dent in total health care costs," the authors wrote.

The question instead is whether quality will suffer as overall payments are limited with only a mild deterrent to undertreatment, Swaminathan said. "Going forward, the use of ESAs might fall since the FDA has recently removed the requirement that targeted hemoglobin levels in ESRD patients should at least be 10 grams/deciliter," he said. "This fact plus the incentives provided by bundled payments may see hemoglobin levels decline with a concomitant increase in the rate of blood transfusions, increased hospitalizations and hence increased costs."

But it is also possible that quality levels will remain high and Medicare will have gained a handle on ESRD costs. What would help, Swaminathan said, is better medical evidence of the best hemoglobin levels to target.

"Then, Medicare may be able to pin their pay-for-performance metrics more closely with the evidence," he said. "If that is done, the twin pillars of the recent dialysis payment reform -- pay-for-performance and bundling -- may become successful."

And then those twin pillars would likely be seen as a model for other services within Medicare, he predicted.

In addition to Swaminathan, the paper's other authors are Vincent Mor and Amal Trivedi of Brown and the Providence Veterans Affairs Medical Center, and Rajnish Mehrotra of the University of Washington.


Story Source:

The above story is based on materials provided by Brown University. Note: Materials may be edited for content and length.


Journal Reference:

  1. S. Swaminathan, V. Mor, R. Mehrotra, A. Trivedi. Medicare's Payment Strategy For End-Stage Renal Disease Now Embraces Bundled Payment And Pay-For-Performance To Cut Costs. Health Affairs, 2012; 31 (9): 2051 DOI: 10.1377/hlthaff.2012.0368

Cite This Page:

Brown University. "Medicare kidney spending reaches crucial moment." ScienceDaily. ScienceDaily, 4 September 2012. <www.sciencedaily.com/releases/2012/09/120904162529.htm>.
Brown University. (2012, September 4). Medicare kidney spending reaches crucial moment. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2012/09/120904162529.htm
Brown University. "Medicare kidney spending reaches crucial moment." ScienceDaily. www.sciencedaily.com/releases/2012/09/120904162529.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Texas Nurse Nina Pham Cured of Ebola

Texas Nurse Nina Pham Cured of Ebola

AFP (Oct. 25, 2014) — An American nurse who contracted Ebola while caring for a Liberian patient in Texas has been declared free of the virus and will leave the hospital. Duration: 01:01 Video provided by AFP
Powered by NewsLook.com
IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) — IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) — A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) — The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins